Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DeepMatter acquires AI specialist ChemIntelligence

28 Jun 2022 07:00

RNS Number : 3779Q
DeepMatter Group PLC
28 June 2022
 

 

28 June 2022

 

DeepMatter acquires AI specialist ChemIntelligence

 

DeepMatter Group Plc (AIM: DMTR, "Deepmatter", the "Group"), the digital chemistry data and software company, has acquired ChemIntelligence SAS ("ChemIntelligence") in a transaction valuing the business at up to £0.42m.

 

ChemIntelligence (https://chemintelligence.com/) has artificial intelligence (AI) that is used to develop chemical products and reactions faster. The business is based in Lyon, a city known as a digital centre and its strong links to France's Chemistry Valley.

 

The acquisition brings intellectual property and expertise that complements the Group's chemical reaction data, data collection platform and AI capabilities. It will also broaden Deepmatter's technical expertise in chemical formulation, which will enable the Group to expand its offering and address a broader customer base. The two businesses will benefit from combined sales and marketing, operations, customer support and research resources.

 

ChemIntelligence enables the prediction of the properties of molecules, materials and formulations, suggesting the most relevant experiments to perform in a secure, certified end-to-end cloud environment.

 

ChemIntelligence unaudited revenue for the financial year ended 31 December 2021 was €0.12m, with profit before tax of €0.02m. The gross assets of the Company as at 31 December 2021 were €0.12m

 

Mark Warne, CEO of DeepMatter, commented:

 

"The ChemIntelligence team bring considerable expertise which will strengthen our data and AI capabilities with our current customers. It will also allow us to reach into new customer segments.

 

"Our vision is to combine our proprietary chemistry data with proprietary algorithms in order to transform how medicines and other chemical molecules are made, significantly improving productivity, discovery and sustainability in the field of chemistry." 

 

The consideration will be payable in three tranches. The initial consideration will comprise the issue to the vendor of ChemIntelligence (the "Vendor") 23,333,334 Ordinary Shares (the "Initial Consideration Shares"), which based on the closing share price of the Company on 27 June 2022 (being the last business day prior to the release of this announcement) has a value of £0.026 million.

 

A maximum of 186,666,666 additional Ordinary Shares ("Deferred Consideration Shares") will be issued to the Vendor depending on both the share price performance of Deepmatter and the financial performance of ChemIntelligence for the year ended 31 December 2022 and the year ended 31 December 2023. The vendor has agreed to lock up provisions covering 24 months after the issue of Ordinary Shares via the Initial Consideration and 24 months after the earliest issue date of the Deferred Consideration. Deepmatter has the option to make any of the Consideration payable in cash.

The maximum value that Deepmatter will pay for ChemIntelligence is £0.42m.

 

An application will be made to London Stock Exchange plc for the 23,333,334 Initial Consideration Shares to be admitted to trading on AIM. The Initial Consideration Shares will be issued credited as fully paid and will rank pari passu with the existing Ordinary Shares, including the right to receive all dividends and other distributions (if any) declared, made or paid on or in respect of such shares after the date of their issue. It is expected that admission of the Initial Consideration Shares to trading on AIM ("Admission") will become effective and that dealings in the Subscription Shares will commence on AIM at 8.00am on 4 July 2022.

 

Following Admission, the Company will have a total of 4,033,230,615 Ordinary Shares in issue. With effect from Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

 

For more information contact

 

DeepMatter Group Plc Fraser Benson, Chief Financial Officer 0141 548 8156

Canaccord Genuity Limited (Nominated Advisor and Broker) Bobbie Hilliam 020 7523 8000

Meare Consulting Adrian Duffield 07990 858548

DeepMatter's SmartChemistry™ platform enables scientists across a range of industries, including pharma, biotech, agri-science, scientific publishers and contract research organisations (CROs), to easily capture, access and exploit the vast amounts of data created in chemical reactions.

 

DeepMatter integrates its proprietary chemistry data and proprietary software to significantly improve productivity, efficiency, discovery, safety and sustainability of chemical reactions for its customers.

 

DeepMatter's SmartChemistry™ platform capitalises on the combination of its cloud technology, low cost-sensors, connectivity to laboratory hardware and high-performance computing trends such as artificial intelligence (AI).

 

Visit: www.deepmatter.io and follow @deepmattergroup

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFRMBTMTTTTLT
Date   Source Headline
5th Jan 20237:00 amRNSCancellation - DEEPMATTER GROUP PLC
4th Jan 20238:00 amRNSHolding(s) in Company
29th Dec 20225:30 pmRNSDeepmatter Group
20th Dec 20227:00 amRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
19th Dec 20223:44 pmRNSResult of General Meeting
19th Dec 20222:05 pmRNSSecond Price Monitoring Extn
19th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 202211:05 amRNSSecond Price Monitoring Extn
19th Dec 202211:00 amRNSPrice Monitoring Extension
15th Dec 20224:40 pmRNSSecond Price Monitoring Extn
15th Dec 20224:35 pmRNSPrice Monitoring Extension
15th Dec 20222:05 pmRNSSecond Price Monitoring Extn
15th Dec 20222:00 pmRNSPrice Monitoring Extension
9th Dec 202211:05 amRNSSecond Price Monitoring Extn
9th Dec 202211:00 amRNSPrice Monitoring Extension
8th Dec 20228:46 amRNSHolding(s) in Company
2nd Dec 20227:00 amRNSPosting of Circular
1st Dec 20227:00 amRNSProposed Cancellation of Ordinary Shares
24th Nov 20227:00 amRNSCorporate Update
31st Oct 202212:00 pmRNSDirector/PDMR Shareholding
26th Oct 20227:00 amRNSTrading Update
26th Oct 20227:00 amRNSDeepMatter signs multi-year license agreement
26th Aug 20221:25 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHalf Year Results
28th Jun 20227:00 amRNSDeepMatter acquires AI specialist ChemIntelligence
20th Jun 20224:41 pmRNSSecond Price Monitoring Extn
20th Jun 20224:35 pmRNSPrice Monitoring Extension
20th Jun 20222:05 pmRNSSecond Price Monitoring Extn
20th Jun 20222:00 pmRNSPrice Monitoring Extension
20th Jun 202211:05 amRNSSecond Price Monitoring Extn
20th Jun 202211:00 amRNSPrice Monitoring Extension
9th Jun 20225:26 pmRNSHolding(s) in Company
27th May 20222:30 pmRNSResult of AGM
25th May 20222:30 pmRNSIssue of Equity and TVR
23rd May 20227:00 amRNSDirectorate Change
20th May 20227:00 amRNSContract extension
11th May 20227:00 amRNSContract
27th Apr 20227:00 amRNSFinal Results
30th Mar 20224:00 pmRNSHolding(s) in Company
1st Mar 20227:00 amRNSContract
14th Feb 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20223:20 pmRNSHolding(s) in Company
26th Jan 20223:15 pmRNSHolding(s) in Company
26th Jan 20227:00 amRNSHolding(s) in Company
25th Jan 20225:45 pmRNSHolding(s) in Company
25th Jan 202212:30 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSDirector/PDMR Shareholding
25th Jan 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.